

C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

<https://marketpublishers.com/r/C7745668C2EEN.html>

Date: October 2018

Pages: 139

Price: US\$ 3,000.00 (Single User License)

ID: C7745668C2EEN

Abstracts

This report can be delivered to the clients within 48 hours

'C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018', report provides comprehensive insights about marketed and pipeline drugs across this mechanism of action. The report provides the detailed analysis of 20+ products along with 18+ companies involved. Dompe Farmaceutici, BioLineRx, and X4 Pharmaceuticals are among the developers of most promising pipeline products.

Products covered by Phase

Marketed Products

Phase III, Phase II and Phase I

Pre-clinical and Discovery

Overview of pipeline development activities for C-X-C Chemokine Receptor (CXCR) Inhibitors

Pipeline analysis of 20+ therapeutic drugs include but are not limited to drug description and development activities focusing on clinical and non-clinical results, designations, collaborations & licensing deals, grants, technology and patent details. Report contains the development and sale activities for marketed drugs.

Therapeutic segmentation of products for C-X-C Chemokine Receptor (CXCR) Inhibitors

The report comprises of comparative pipeline therapeutics assessment by development stage, therapy type, molecule type, and administration route across this Immunotherapy.

METHODOLOGY

Data used in the report are sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts.

Information and data from the secondary sources have been obtained from various printable and non-printable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

SCOPE

The report provides competitive pipeline landscape of C-X-C Chemokine Receptor (CXCR) Inhibitors

The report provides the marketed drugs information including its sales, development activities and details of patent expiry

The report provides the insight of current and future market for C-X-C Chemokine Receptor (CXCR) Inhibitors

The report provides pipeline products under drug profile section which includes product description, MOA, licensors & collaborators, development partner and chemical information

Coverage of the C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline on the basis of target, MOA, route of administration, technology involved and molecule type

The report reviews key players involved in the therapeutics development for C-X-C Chemokine Receptor (CXCR) Inhibitors and also provide company profiling

Pipeline products coverage based on various stages of development ranging from late stage till discovery stage

Provides pipeline assessment by monotherapy and combination therapy products, stage of development and molecule type

REASONS TO BUY

Identify emerging players with potentially strong product information and create effective counter-strategies to gain competitive advantage

Establish a comprehensive understanding of the current pipeline scenario C-X-C Chemokine Receptor (CXCR) Inhibitors to formulate effective R&D strategies

Assess challenges and opportunities that influence C-X-C Chemokine Receptor (CXCR) Inhibitors R&D

Gather impartial perspective of strategies of the emerging competitors having potentially lucrative portfolio in this space and create effective counter strategies to gain competitive advantage

Identify the relationship between the drugs and use it for target finding, drug repurposing, and precision medicine

Devise corrective measures for pipeline projects by understanding C-X-C Chemokine Receptor (CXCR) Inhibitors pipeline depth and focus of target therapeutics

Developing strategic initiatives to support your drug development activities

Devise in licensing and out licensing strategies by identifying prospective partners with progressing projects for C-X-C Chemokine Receptor (CXCR) Inhibitors to enhance and expand business potential and scope

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Our extensive domain knowledge on therapy areas support the client in decision-making process regarding their therapeutic portfolio by identifying the reason behind the inactive drugs

Gaining a full picture of the Competitive Landscape for Evidence based Decisions

Contents

- Executive Summary
- Overview
- Introduction
- Structure of CXC Receptors
- Key CXCR Inhibitors as Drug Targets
- CXCR4 Inhibitor
- Mechanism of Action
- CXCR4 in Different Indications
- CXCR4 in Rheumatoid Arthritis
- CXCR4 and WHIM syndrome
- CXCR4 and Metabolic Disorders
- Competitive Landscape – Active Products
- Active Pipeline Coverage by Indication
- Marketed and Pipeline Products
- Marketed Products
- Mozobil: Sanofi Genzyme
- Product Description
- Regulatory Milestones
- Research and Development
- Other Clinical Activities
- Product Development Activities
- Global Sales of Mozobil
- Historical and Forecasted Global Sales (2015-2027)
- Mozobil - Analyst Insights
- CXCR Inhibitors Class Share Evolution
- Pipeline Therapeutics (Active Products)
- Pipeline Therapeutics (Inactive Products)
- Comparative Analysis
- Late Stage Products (Phase III)
- Comparative Analysis
- Reparixin: Dompe Farmaceutici
- Product Description
- Research and Development
- Product Development Activities
- Reparixin Forecasted Sales
- Reparixin - Analyst Insights
- (The list continues)

Mid Stage Products (Phase II)
Comparative Analysis
Early Stage Products (Phase I)
Comparative Analysis
Pre-clinical and Discovery Stage Products
Comparative Analysis
Therapeutic Assessment: Active Products
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Dormant & Discontinued Products
Comparative Analysis
Appendix

List Of Tables

LIST OF TABLES

Table 1: Active Pipeline Coverage by Indication

Table 2: Marketed and Pipeline Products

Table 3: Mozobil Historical and Forecasted Global Sales (2015-2027)

Table 4: Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors

Table 5: Late Stage Products (Phase III)

Table 6: Reparixin Forecasted Sales (2020-2027)

Table 7: BL-8040 Forecasted Sales (2020-2027)

Table 8: X4P-001 Forecasted Sales (2020-2027)

Table 9: Mid Stage Products (Phase II)

Table 10: Early Stage Products (Phase I)

Table 11: Pre-clinical and Discovery Stage Products

Table 12: Assessment by Route of Administration

Table 13: Assessment by Stage and Route of Administration

Table 14: Assessment by Molecule Type

Table 15: Assessment by Stage and Molecule Type

Table 16: Dormant Products

Table 17: Discontinued Products

List Of Figures

LIST OF FIGURES

- Figure 1: Structure of CXCR Inhibitors
- Figure 2: Crystal Structure of the CXCR1 and CXCR2
- Figure 3: CXCL8 Gene Regulation and Signaling Cascades Downstream of CXCL8-mediated CXCR1/2 Activation
- Figure 4: CXCR 1 and 2 Mechanism in Inflammatory Diseases
- Figure 5: Crystal Structure of the Chemokine Receptor CXCR4
- Figure 6: CXCR4 Mechanism in Cancer
- Figure 7: CXCR4 mechanism in HIV Infection
- Figure 8: CXCR4 Mechanism in Rheumatoid Arthritis
- Figure 9: CXCR4 Mechanism in Cancer
- Figure 10: Marketed and Pipeline Products
- Figure 11: Mozobil Historical and Forecasted Global Sales (2015-2027)
- Figure 12: Total Products for C-X-C Chemokine Receptor (CXCR) Inhibitors
- Figure 13: Late Stage Products (Phase III)
- Figure 14: Reparixin Forecasted Sales (2020-2027)
- Figure 15: BL-8040 Forecasted Sales (2020-2027)
- Figure 16: X4P-001 Forecasted Sales (2020-2027)
- Figure 17: Mid Stage Products (Phase II)
- Figure 18: Early Stage Products (Phase I)
- Figure 19: Pre-clinical and Discovery Stage Products
- Figure 20: Assessment by Route of Administration
- Figure 21: Assessment by Stage and Route of Administration
- Figure 22: Assessment by Molecule Type
- Figure 23: Assessment by Stage and Molecule Type
- Figure 24: Dormant & Discontinued Products

I would like to order

Product name: C-X-C Chemokine Receptor (CXCR) Inhibitors - Competitive Landscape, Market and Pipeline Analysis, 2018

Product link: <https://marketpublishers.com/r/C7745668C2EEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C7745668C2EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

